AbCheck provides a unique source of therapeutic antibodies with one of the industry’s most versatile technology platforms. We provide high-quality drug candidates through discovery collaborations or strategic research partnerships based on flexible business terms including royalty-free agreements. We generate target specific human antibody domains which can be used in distinct therapeutic formats. AbCheck was founded in 2009 and is a spin-out of Affimed’s technology discovery platform. AbCheck is a wholly owned subsidiary of Affimed GmbH, a biopharmaceutical company developing highly targeted cancer immunotherapies.
We are a highly skilled and experienced team operating transparently and in agreement with the highest ethical and corporate governance standards – mutual respect, integrity and trust are our foundation. AbCheck fosters a close, collaborative working relationship with our clients. Our experience has demonstrated that this type of close interaction is very valuable in the development of successful projects. We insist on the highest quality standard, challenge conventional thinking within our team and cultivate rigorous problem solving, resulting in best solutions and scientific innovations that help to deliver optimal results in a timely fashion.